TY  - CHAP
M1  - Book, Section
TI  - Cardiovascular Outcomes and Home Hemodialysis
A1  - Wiegley, Nasim
A1  - Morfín, José A.
A2  - Knicely, Daphne H.
A2  - Abdel-Rahman, Emaad M.
A2  - Greenberg, Keiko I.
PY  - 2021
T2  - Handbook of Home Hemodialysis
AB  - Cardiovascular  disease  (CVD)  is  prevalent  in  patients  with  chronic  kidney  disease  (CKD),  and  has  been  reported  to  be  more  than  twice  as  likely  to  develop  in  patients  with  CKD  compared  to  the  general  Medicare  population.1  CVD  prevalence  increases  with  progression  of  CKD,  and  is  the  leading  cause  of  death  in  individuals  with  advanced  CKD,  particularly  among  those  requiring  dialysis.  Left  ventricular  hypertrophy  (LVH)  is  a  maladaptive  response  to  volume/pressure  overload  that  leads  to  cardiomyopathy.  LVH  is  quite  prevalent  in  end-stage  kidney  disease  (ESKD),  with  reported  rates  as  high  as  90%,  and  thus  is  an  important  predictor  of  CVD  morbidity  and  mortality.2  Anemia,  mineral  bone  metabolism,  uremia/inflammation,  and  most  importantly  hypertension  (HTN)  have  all  been  implicated  in  the  development  of  LVH.3  As  a  consequence,  the  overall  rates  of  CVD-related  hospitalizations  and  mortality  remain  high  in  ESKD,  despite  a  slight  reduction  over  the  past  decade,  pointing  toward  the  need  for  interventions  that  improve  CVD  outcomes  in  this  vulnerable  patient  population.1  
SN  - 
PB  - McGraw Hill
CY  - New York, NY
Y2  - 2024/04/23
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1178969816
ER  -